Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Acute myeloid leukemia: treatment of adults under 60 years [Review]

Burnett, Alan Kenneth 2002. Acute myeloid leukemia: treatment of adults under 60 years [Review]. Reviews in Clinical and Experimental Hematology 6 (1) , pp. 26-45. 10.1046/j.1468-0734.2002.00058.x

Full text not available from this repository.

Abstract

Current chemotherapy with advanced supportive care will enable 75-80% of acute myeloid leukemia patients aged 60 years or under to enter complete remission. Several regimens achieve broadly similar results. For patients who enter complete remission, the overall relapse risk is now 45-50%, but this is highly variable and is primarily determined by the biology of the disease. Cytogenetics are strongly influential in response to induction and consolidation with t(15:17), t(8:21) and inv(16) either occurring alone or with additional abnormalities having a relapse risk of about 30% and complex changes, abnormal 3q or abnormalities of chromosomes 5 and 7 resulting in a lower remission rate and a rapid relapse cumulating to 80%. FLT3 mutations occur in 25% of patients and are an independent predictor of relapse and, when combined with cytogenetics, adversely influence the prognosis in each cytogenetic risk group. Recent prospective collaborative group trials have endeavored to evaluate allogeneic and autologous bone marrow transplant against or in addition to consolidation chemotherapy. Suboptimal treatment delivery emerged as a problem. When the results were reported on an intention-to-treat basis, no overall survival advantage was consistently seen for either type of transplant. However, a significant reduction in risk of relapse was usually seen overall and within risk groups. Analysis within risk groups suggests that transplant is not indicated in good risk disease and continues to require evaluation in standard or poor risk patients. It is probable that traditional dose intensification has now reached its limits of tolerability, so new approaches will be required for further progress to be made. Modulation of chemoresistance mechanisms or immunologically directed chemotherapy represent immediate prospects for clinical study.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: AcuteDisease,Adult,AntineoplasticAgents/administration&dosage,AntineoplasticAgents/therapeuticuse,CombinedModalityTherapy,HematopoieticStemCellTransplantation/mortality,Humans,Leukemia Myeloid/mortality,Leukemia Myeloid/therapy*,Middle Aged,Survival Analysis,Treatment Outcome Substances Antineoplastic Agents
Additional Information: discussion pages 86-7 Full Text Sources Blackwell Publishing EBSCO Other Literature Sources Labome Researcher Resource - ExactAntigen/Labome
Publisher: Wiley
ISSN: 1127-0020
Related URLs:
Last Modified: 25 Jun 2017 04:41
URI: http://orca.cf.ac.uk/id/eprint/58432

Citation Data

Cited 36 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item